Background: Transplant Renal Artery Stenosis (TRAS) is the main vascular complication of kidney transplantation. For research and treatment purposes, several authors consider critical renal artery stenosis to be greater than 50%, and percutaneous intervention is indicated in this scenario. However, there are no reports in the current literature on the evolution of patients with less than 50% stenosis.
Method: Retrospective study includes data from all patients that were submitted to kidney transplantation and were suspected TRAS after transplantation with stenosis under 50% independent on age, who were referred for angiography at a single center between January 2007 and December 2014.
Results: During this period, 6,829 kidney transplants were performed at Hospital do Rim, 313 of them had clinical suspicion of TRAS and 54 were those who presented no-significant stenosis. The average age was 35.93 years old, the predominant gender was male and most individuals (94.4%) were submitted to dialysis before transplantation. Transplants, in most cases in this group, occurred from a deceased donor, 66.7%. The time between transplantation and angiography was less than one year in 79.6% of patients and all presented no-significant TRAS. Creatinine levels, Systolic Blood Pressure, Diastolic Blood Pressure and the glomerular filtration rate improved over the long term. The outcomes found were death and renal loss.
Conclusion: Age, sex and ethnic group of patients are factors that did not interfere with the frequency of renal artery stenosis. The outcomes showed that in the long term most patients evolve well, and have improved quality of life and kidney function, although there are cases of death and kidney loss.
Competing interest reported. Hélio Tedesco Silva Júnior has received research grants and travel and consulting honoraria from Novartis, Sanofi and Pfizer. The remaining authors have no competing interests to disclose.
Loading...
Posted 10 May, 2021
On 02 Dec, 2021
On 10 Jun, 2021
Received 06 Jun, 2021
On 24 May, 2021
Invitations sent on 12 May, 2021
On 07 May, 2021
On 07 May, 2021
On 07 May, 2021
On 02 Apr, 2021
Posted 10 May, 2021
On 02 Dec, 2021
On 10 Jun, 2021
Received 06 Jun, 2021
On 24 May, 2021
Invitations sent on 12 May, 2021
On 07 May, 2021
On 07 May, 2021
On 07 May, 2021
On 02 Apr, 2021
Background: Transplant Renal Artery Stenosis (TRAS) is the main vascular complication of kidney transplantation. For research and treatment purposes, several authors consider critical renal artery stenosis to be greater than 50%, and percutaneous intervention is indicated in this scenario. However, there are no reports in the current literature on the evolution of patients with less than 50% stenosis.
Method: Retrospective study includes data from all patients that were submitted to kidney transplantation and were suspected TRAS after transplantation with stenosis under 50% independent on age, who were referred for angiography at a single center between January 2007 and December 2014.
Results: During this period, 6,829 kidney transplants were performed at Hospital do Rim, 313 of them had clinical suspicion of TRAS and 54 were those who presented no-significant stenosis. The average age was 35.93 years old, the predominant gender was male and most individuals (94.4%) were submitted to dialysis before transplantation. Transplants, in most cases in this group, occurred from a deceased donor, 66.7%. The time between transplantation and angiography was less than one year in 79.6% of patients and all presented no-significant TRAS. Creatinine levels, Systolic Blood Pressure, Diastolic Blood Pressure and the glomerular filtration rate improved over the long term. The outcomes found were death and renal loss.
Conclusion: Age, sex and ethnic group of patients are factors that did not interfere with the frequency of renal artery stenosis. The outcomes showed that in the long term most patients evolve well, and have improved quality of life and kidney function, although there are cases of death and kidney loss.
Competing interest reported. Hélio Tedesco Silva Júnior has received research grants and travel and consulting honoraria from Novartis, Sanofi and Pfizer. The remaining authors have no competing interests to disclose.
Loading...